{"id":"ly3537031","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Gastrointestinal disorders"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By simultaneously activating GLP-1 and GIP receptors, LY3537031 enhances insulin secretion in response to glucose, slows gastric emptying, and increases satiety. This dual mechanism produces greater glycemic control and weight reduction compared to single GLP-1 agonists. The drug is being developed as a once-weekly injectable for metabolic disorders.","oneSentence":"LY3537031 is a GLP-1 and GIP receptor dual agonist that activates both incretin pathways to improve glucose control and promote weight loss.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:53.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management"}]},"trialDetails":[{"nctId":"NCT07410507","phase":"PHASE2","title":"A Study of Brenipatide in Adult Participants With Schizophrenia","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-10","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT07412756","phase":"PHASE3","title":"A Study of Brenipatide in Adult Participants With Major Depressive Disorder","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-09","conditions":"Depressive Disorder, Major","enrollment":1000},{"nctId":"NCT07219173","phase":"PHASE2","title":"A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Asthma","enrollment":531},{"nctId":"NCT07219966","phase":"PHASE3","title":"A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-15","conditions":"Alcohol Use Disorder","enrollment":1100},{"nctId":"NCT07223840","phase":"PHASE2","title":"A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-03","conditions":"Smoking","enrollment":222},{"nctId":"NCT07219953","phase":"PHASE3","title":"A Study of Brenipatide in Participants With Alcohol Use Disorder","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-16","conditions":"Alcohol Use Disorder","enrollment":1100},{"nctId":"NCT07286175","phase":"PHASE2","title":"A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-24","conditions":"Bipolar Disorder","enrollment":400},{"nctId":"NCT07165015","phase":"PHASE1","title":"A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-09-18","conditions":"Renal Impairment, Healthy, Renal Insufficiency","enrollment":32},{"nctId":"NCT07476118","phase":"PHASE1","title":"A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-03","conditions":"Obesity, Overweight","enrollment":150},{"nctId":"NCT07420283","phase":"PHASE2","title":"A Study of Brenipatide in Participants With Opioid Use Disorder","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-13","conditions":"Opioid Use Disorder","enrollment":465},{"nctId":"NCT06606106","phase":"PHASE1","title":"A Study of LY3537031 in Overweight, Obese, and Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-09-05","conditions":"Overweight, Obesity","enrollment":302},{"nctId":"NCT07202871","phase":"PHASE1","title":"A Study of How the Body Absorbs LY3537031","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-03","conditions":"Healthy","enrollment":46},{"nctId":"NCT07165002","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-20","conditions":"Healthy, Hepatic Insufficiency","enrollment":32},{"nctId":"NCT04648865","phase":"PHASE1","title":"A Study of LY3537031 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-12-09","conditions":"Healthy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Brenipatide"],"phase":"phase_3","status":"active","brandName":"LY3537031","genericName":"LY3537031","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY3537031 is a compound studied in clinical trials, including those for asthma, renal impairment, and end stage renal disease. It is a dual agonist of glucagon-like peptide-1 (GLP-1) receptors and gastric inhibitory polypeptide (GIP) receptors, similar to brenipatide.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}